|
Malignant neoplasm of stomach
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
After that, Flot2-specific siRNA was used to decrease the Flot2 expression in gastric cancer AGS and SGC7901 cells.
|
24854103 |
2014 |
|
Stomach Carcinoma
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
After that, Flot2-specific siRNA was used to decrease the Flot2 expression in gastric cancer AGS and SGC7901 cells.
|
24854103 |
2014 |
|
Malignant Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Altered expression of flotillin-2 (FLOT2) has been identified in certain types of cancer, including breast cancer and melanoma; however, to the best of our knowledge, the association between the FLOT2 expression level and colorectal cancer (CRC) remains to be determined.
|
30854055 |
2019 |
|
Primary malignant neoplasm
|
0.090 |
AlteredExpression
|
group |
BEFREE |
Altered expression of flotillin-2 (FLOT2) has been identified in certain types of cancer, including breast cancer and melanoma; however, to the best of our knowledge, the association between the FLOT2 expression level and colorectal cancer (CRC) remains to be determined.
|
30854055 |
2019 |
|
Malignant neoplasm of breast
|
0.070 |
AlteredExpression
|
disease |
BEFREE |
Altered expression of flotillin-2 (FLOT2) has been identified in certain types of cancer, including breast cancer and melanoma; however, to the best of our knowledge, the association between the FLOT2 expression level and colorectal cancer (CRC) remains to be determined.
|
30854055 |
2019 |
|
Breast Carcinoma
|
0.070 |
AlteredExpression
|
disease |
BEFREE |
Altered expression of flotillin-2 (FLOT2) has been identified in certain types of cancer, including breast cancer and melanoma; however, to the best of our knowledge, the association between the FLOT2 expression level and colorectal cancer (CRC) remains to be determined.
|
30854055 |
2019 |
|
melanoma
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
Altered expression of flotillin-2 (FLOT2) has been identified in certain types of cancer, including breast cancer and melanoma; however, to the best of our knowledge, the association between the FLOT2 expression level and colorectal cancer (CRC) remains to be determined.
|
30854055 |
2019 |
|
Tumor Cell Invasion
|
0.090 |
GeneticVariation
|
phenotype |
BEFREE |
An in-frame deletion mutant of the ESA_01081 homolog and its cognate complementation strain were constructed and characterized for pathogenesis (adhesion/invasion potentials to human intestinal cells and in vivo rat pup challenge assay), biofilm formation, resistance to oxidative stress and induction of IL-8 secretion.
|
22770741 |
2012 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Based largely on studies in xenograft models, flotillin-2 has been implicated in the progression of multiple types of human tumors, including breast cancer.
|
23146906 |
2013 |
|
Tumor Cell Invasion
|
0.090 |
Biomarker
|
phenotype |
BEFREE |
CD44(+) CD24(low+) populations contain subsets of ALDH1(+) and ESA(+) cells, yield more frequent spheres and/or T-ISC in limiting dilution assays, preferentially express metastatic gene signatures and show greater motility, invasion and, in the MDA-MB-231 model, metastatic potential.
|
23982961 |
2013 |
|
Tumor Cell Invasion
|
0.090 |
AlteredExpression
|
phenotype |
BEFREE |
Clinical analysis identified that increased expression of FLOT2 was associated with the depth of invasion, lymph node metastasis, distant metastasis and American Joint Committee on Cancer stage of CRCs.
|
30854055 |
2019 |
|
Neoplasm Metastasis
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
Clinical analysis identified that increased expression of FLOT2 was associated with the depth of invasion, lymph node metastasis, distant metastasis and American Joint Committee on Cancer stage of CRCs.
|
30854055 |
2019 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Disulfiram and doxorubicin cooperated to induce cell death as well as cellular senescence, and targeted the ESA(+)/CD24(-/low)/CD44(+) cancer stem cell population.
|
23974104 |
2013 |
|
Primary malignant neoplasm
|
0.090 |
Biomarker
|
group |
BEFREE |
Disulfiram and doxorubicin cooperated to induce cell death as well as cellular senescence, and targeted the ESA(+)/CD24(-/low)/CD44(+) cancer stem cell population.
|
23974104 |
2013 |
|
Coronary heart disease
|
0.020 |
Biomarker
|
disease |
BEFREE |
DNA methylation levels of the candidate genes FLOT1, FLOT2 and SOAT1 were measured in peripheral blood leukocytes (PBLs) from 99 patients diagnosed with CHD and 89 control subjects without CHD.
|
31684966 |
2019 |
|
Neoplasm Metastasis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Ectopic Flot2 could significantly reverse miR-485-mediated inhibition of metastasis and EMT, demonstrating Flot2 downregulation is involved in function of miR-485.
|
27262438 |
2016 |
|
Venous Thromboembolism
|
0.010 |
GeneticVariation
|
phenotype |
BEFREE |
Eur J Anaesthesiol 2018; 35:73-76.A synopsis of all recommendations can be found in the following accompanying article: Afshari A, Ageno W, Ahmed A, et al., for the ESA VTE Guidelines Task Force.
|
28901992 |
2018 |
|
Tumor Progression
|
0.070 |
AlteredExpression
|
phenotype |
BEFREE |
Expression of flotillin-2 in human non-small cell lung cancer and its correlation with tumor progression and patient survival.
|
25755751 |
2015 |
|
Tumor Cell Invasion
|
0.090 |
AlteredExpression
|
phenotype |
BEFREE |
Following this, we examined the effects of GLI3 knockdown on CD44 and ESA expression, colony and sphere formation capability, stem-related gene expression, proliferation and invasion.
|
30272273 |
2018 |
|
Adenocarcinoma of lung (disorder)
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Furthermore, FLOT2 (flotillin-2) identified as a direct target of miR-133, and FLOT2 expression levels were inversely correlated with miR-133 expression levels in human lung adenocarcinoma specimens.
|
28503944 |
2018 |
|
Neoplasm Metastasis
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
Furthermore, inhibiting Flot-2 expression impaired the malignancy of the highly metastatic NPC cell line 5-8F by constraining its growth and proliferation, mobility and migration, and decreasing the capacity of 5-8F cells to metastasize in nude mice.
|
26206082 |
2015 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Furthermore, small hairpin RNA-mediated CBX7 knockdown in breast epithelial and cancer cells increased the CD44(+)/CD24(-)/ESA(+) cell population and reinforced in vitro self-renewal and in vivo tumor-initiating ability.
|
25351982 |
2015 |
|
mathematical ability
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Gene discovery and polygenic prediction from a genome-wide association study of educational attainment in 1.1 million individuals.
|
30038396 |
2018 |
|
Malignant neoplasm of breast
|
0.070 |
Biomarker
|
disease |
BEFREE |
Here, we report that upregulation of hyaluronan synthase 2 (HAS2) occurs in highly metastatic breast cancer stem-like cells (CSC) defined by CD44(+)/CD24(-)/ESA(+) phenotype, where it plays a critical role in the generation of a prometastatic microenvironment in breast cancer.
|
22113945 |
2012 |
|
Breast Carcinoma
|
0.070 |
Biomarker
|
disease |
BEFREE |
Here, we report that upregulation of hyaluronan synthase 2 (HAS2) occurs in highly metastatic breast cancer stem-like cells (CSC) defined by CD44(+)/CD24(-)/ESA(+) phenotype, where it plays a critical role in the generation of a prometastatic microenvironment in breast cancer.
|
22113945 |
2012 |